Hedge Funds Are Buying Acceleron Pharma Inc (XLRN)

As one would reasonably expect, key money managers have jumped into Acceleron Pharma Inc (NASDAQ:XLRN) headfirst. Benjamin A. Smith’s Laurion Capital Management assembled the most outsized position in Acceleron Pharma Inc (NASDAQ:XLRN), followed by Peter Kolchinsky’s RA Capital Management, which initiated a $11.5 million position during the quarter. The following funds were also among the new XLRN investors: Lei Zhang’s Hillhouse Capital Management, Jim Simons’s Renaissance Technologies, and Cliff Asness’s AQR Capital Management.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Acceleron Pharma Inc (NASDAQ:XLRN) but similarly valued. These stocks are The Buckle, Inc. (NYSE:BKE), Endurance International Group Hldgs Inc (NASDAQ:EIGI), Globalstar, Inc. (PINK:GSAT), and Methode Electronics Inc. (NYSE:MEI). This group of stocks’ market caps resemble XLRN’s market cap.

As you can see these stocks had an average of 14 hedge funds with bullish positions and the average amount invested in these stocks was $102 million. That figure was $158 million in XLRN’s case. Globalstar, Inc. (PINK:GSAT) is the most popular stock in this table. On the other hand Endurance International Group Hldgs Inc (NASDAQ:EIGI) is the least popular one with only 7 bullish hedge fund positions. Compared to these stocks Acceleron Pharma Inc (NASDAQ:XLRN) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: none.